Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Double Bond Pharmaceutical and Closter Pharma perform experience exchange

In week 44, i.e during 29/10 – 2/11, eight doctors from leading hospitals in Colombia will meet and exchange experiences with developers, manufacturers and users of Temodex in Belarus. During three days, they have the opportunity to be with their Belarussian colleagues and see with their own eyes how Temodex is manufactured and used on site. "It is gratifying to meet the enthusiasm of our colleagues from Colombia and see their zeal to learn more about Temodex" -commented Igor Lokot, CEO of Double Bond Pharmaceutical. "I am proud to be part of introducing our innovative product in Latin

Storytel prepares for launch in Singapore

As a step in Storytel’s pronounced international expansion, a new office in Singapore will open for business during the autumn of 2018 –– staffed with local employees. The streaming service will go live in 2019, and primarily offer titles in English and Mandarin Chinese. “With its five million inhabitants and its mix of English and Mandarin, Singapore is especially enticing and will be our first foray into Southeast Asia. In addition, Singapore is in the forefront regarding digital content and subscription services, which fits well with the model we offer,” says Stefan Tegenfalk, Head of

Canon to increase its ownership in Axis

Axis majority owner Canon today announced a share purchase agreement that will result in Canon holding almost 98 percent of the shares in Axis AB. Canon intends to apply for delisting of Axis from the Nasdaq Stockholm. Axis will remain an independent entity within the Canon Group."Considering that Canon at the time of their public offering in 2015 expressed an ambition of acquiring all shares in Axis, this was expected to happen at some point. We do not expect this to change daily operations at Axis. Canon has underlined that Axis will continue to be run as an independent company. At the

Handelsbanken’s interim report for January-September 2018 will be presented on October 24

Handelsbanken will present its results for January­‑September 2018 in Stockholm on October 24, 2018, at 8:15 a.m. CET, at a meeting with the media and analysts. The interim report for January‑September 2018 will be published at 6:45 a.m. CET, on October 24, 2018. A telephone conference will be held at 11:15 a.m. CET (5:15 a.m. EST), when Rolf Marquardt, CFO, will present and comment on the results. There will also be time for questions from the participants. UK number: +44 20–3008 9801Swedish number: +46 8–566 426 90US number: +1 855–8315 948 Instructions1.     Dial +xx

BONESUPPORT starts selling CERAMENT® BONE VOID FILLER Direct in the US via its own New Distributor Network

·  25 independent distributors contracted ·  Total of 512 distributor reps now selling CERAMENT BVF ·  New distribution network will positively impact North American reported sales and net margins Lund, Sweden, 08:00 CET, 22 October 2018 - BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, announces that it has started selling CERAMENT® BVF direct via its own US distributor network. Emil Billbäck, BONESUPPORT’s CEO said “The launch of our own US distribution network is a key strategic milestone as we work towards our goal of becoming a global

Canon to increase its ownership of Axis to more than 90 per cent

TOKYO, October 22, 2018—Canon Inc. (“Canon”; Headquarters: Tokyo, Japan; Chairman and CEO: Fujio Mitarai) announced today that the company will increase its ownership of Axis AB (“Axis”; Headquarters: Lund, Sweden; President and CEO: Ray Mauritsson) to more than 90%. Canon has today entered into a share purchase agreement with Elliott International, L.P. and The Liverpool Limited Partnership (together “Elliott”) under which Canon has agreed to purchase 7,825,516 shares in Axis from Elliott at 363.75 Swedish Krona per share (the “Transaction”). As a result of the Transaction, Canon

Change in number of shares in BrainCool AB (publ)

Conversion of convertible notes into shares, as part of the financing agreement announced 23 November 2017The number of convertible notes converted on October 19, 2018, was 20. The number of convertible notes remaining under the first Tranche for future conversion is 5. The number of shares and the number of votes before the conversion was 36 510 233. Through this conversion, and once the shares from the conversion will be registered at Bolagsverket, the number of shares and the number of votes shall have increased by 320 512. The total number of shares and total number of votes after this

Lynparza shows 70% reduction in PFS ovarian cancer

22 October 2018 07:00 BST   SOLO-1 Phase III trial demonstrates Lynparza maintenance therapy cut risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer 60% of patients receiving Lynparza remained progression-free at three years compared to 27% on placebo following platinum-based chemotherapy Lynparza is the only PARP inhibitor to demonstrate an improvement in progression-free survival as 1st-line maintenance treatment for advanced ovarian cancer AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as

Result of Rights Issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.  THIS ANNOUNCEMENT IS AN ADVERTISEMENT AND DOES NOT CONSTITUTE A PROSPECTUS OR PROSPECTUS EQUIVALENT DOCUMENT. NOTHING HEREIN SHALL CONSTITUTE AN OFFERING OF THE SECURITIES REFERRED TO IN THIS ANNOUNCEMENT. ANY DECISION TO PURCHASE, SUBSCRIBE FOR, OTHERWISE ACQUIRE, SELL OR OTHERWISE DISPOSE OF THE SECURITIES REFERRED TO IN THIS

Andreas Wallström to join Swedbank´s Macro Research team as Head of Forecasting and Deputy Head of Macro Research

Swedbank recruits Andreas Wallström as new Head of Forecasting and Deputy Head of Macro Research. Andreas comes from a role as Chief Analyst at Nordea, and has previously held several senior positions and expert assignments, i.e. at the Swedish Ministry of Finance and the European Commission.The Macro Research team is responsible for all global, regional and national macro analysis at Swedbank. The team consists of highly skilled and well-known experts, that among other things, is recognized for the Swedbank Economic Outlook (SEO); a quarterly recurrent report focusing on macro analysis of

Herantis Pharma Oyj: Manager's Transactions - Pekka Simula

Herantis Pharma Oyj: Manager's Transactions - Pekka Simula Herantis Pharma PlcCompany release 22 October 2018 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Pekka Simula Position: Chief Executive Officer Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20181020161010_2 ____________________________________________ Transaction date: 2018-10-18 Venue: FIRST NORTH

Redeye: Doro - Same ol’ situation in phones … but Care is appealing

The previous trends for Doro with stronger EBIT and negative underlying sales growth continued in Q3. We have lately become a lot more optimistic towards the future market prospects for Care, most notably related to the GreatCall bid. However, we see a risk that the traditional phones business could continue to weigh on the total.Read more in our new research update: http://bit.ly/2J81OmJ Start following companies at Redeye to receive the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered Investment Banking. https://www.

Share buy-backs in Telia Company during week 42 2018

During the period  October 15, 2018, until October 19, 2018, Telia Company AB (publ) (LEI code 213800FSR9RNDUOTXO25) has repurchased in total 3,170,000 own shares (ISIN: SE0000667925). The share buy-backs form part of the SEK 5 billion share buy-back programme that Telia Company announced on April 20, 2018. The share buy-back programme, which runs between April 23, 2018, and March 22, 2019, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulation").During the period

Fixed Price Arrangements

Oslo, 22 October 2018: Reference is made to the press release from 17 October 2018 regarding the acquisition of Shell´s Danish upstream assets. As part of the transaction Shell Trading and Supply will continue to have oil lifting rights from the assets via an offtake agreement, the parties have agreed to a fixed price arrangement under the offtake agreement for 80% of the guaranteed liquid production volumes until 30 September 2020 at current market terms. The fixed price arrangement are effective from announcement of the acquisition. Contact: Tel.: +47 22 33 60 00 or email: ir@noreco.

BerGenBio announces interim biomarker and phase II clinical data with selective AXL inhibitor bemcentinib presented at ESMO

Biomarker predicts clinical benefit rate of 70% and overall response rate of 40% in second line NSCLC. Melanoma combination study reports safety and efficacy.Bergen, Norway, 22 October 2018 - BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators have presented interim clinical and biomarker data from BerGenBio’s Phase II clinical programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor, at the ESMO 2018 Congress in Munich (19 - 23 October 2018). Additionally, a pre-clinical study in myelodysplastic syndrome (MDS) was presented. The

Multiconsult ASA profit warning

In what is a seasonally weak quarter, Multiconsult ASA expects to report a small positive EBIT for the third quarter 2018. Losses in LINK arkitektur and International segments, as well as lower than expected earnings in The Greater Oslo Area and Regions Norway are the main sources of disappointing group earnings.LINK arkitektur delivered a loss in the quarter mainly due to low project activity in Denmark as a result of unsuccessful tendering and high tendering activity in Norway. Increased project expenses combined with low project activity in Multiconsult UK and no project activity in

Lucara Announces Launch of First Sale Through Clara

VANCOUVER, October 21, 2018 /CNW/ - (LUC – TSX, LUC – BSE, LUC – Nasdaq Stockholm) Lucara Diamond Corp. (“Lucara” or the “Company”) is pleased to announce that Clara Diamond Solutions, its 100% owned digital sales platform, will commence operations in November 2018 with a select group of large vertically integrated jewelry houses and global diamond manufacturers. Clara is designed to achieve a sustainable premium over existing sales channels, including tenders and long-term supply contracts for sellers, and deliver increased margins for buyers. Eira Thomas, CEO commented: "After

BioArctic is granted a concept patent in Europe for the company’s strategy for disease-modifying treatment of Parkinson’s disease

Stockholm, Sweden, October 21, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant the company’s patent application in Europe, EP09738534.8, for its Parkinson’s disease concept patent. The decision states that the European patent, EP 2 282 758 B1, will enter into force on November 21, 2018. The granted concept patent in Europe protects the company’s innovative treatment strategy for Parkinson’s disease. Corresponding patents have previously been granted in the US and Japan. BioArctic’s patent

Cantargia presented positive phase I clinical data with lead candidate CAN04 at ESMO

· The antibody CAN04 was well tolerated and 6 mg/kg is a safe dose · Effects on biomarkers and 5 of 13 evaluable patients achieved stable disease · 10 mg/kg currently investigated before start of phase IIa during Q4 2018 Cantargia AB (publ) today presented interim results from its clinical Phase I/II trial CANFOUR of lead candidate CAN04 (nidanilimab) in a poster presentation at the ESMO Congress 2018 in Munich, Germany. Data from 16 patients with advanced cancer treated with weekly infusions between 1 mg/kg and 6 mg/kg were presented.The poster presentation – with the title A

Catena Media agrees on amended terms for US assets acquired in December 2016

Catena Media plc (the "Company" or "Catena Media") has agreed with the sellers of U.S. assets acquired in December 2016 to amend the earn-out structure, meaning that the maximum amount of the third and final earn-out payment corresponds to USD 45 million, and that all of Catena Media's U.S. online casino and poker, as well as sports betting revenues now will be included in the calculation. The previous net profit sharing arrangement and put/call options for certain assets are terminated. Through the amended terms Catena Media obtains full control and cost certainty of the U.S. assets

Mekonomen’s rights issue oversubscribed

The information in this announcement may not be made public, announced or distributed, directly or indirectly, in or to Australia, Canada, Japan, USA or any other country where such publication or distribution would violate applicable laws or regulations. See the section Important information at the end of this press announcement. The preliminary result of the rights issue in Mekonomen AB (publ) (”Mekonomen” or the “Company”), for which the subscription period ended on 18 October 2018, shows that the rights issue is oversubscribed. As a result of the rights issue, Mekonomen will receive

Adverty receives funding of SEK 36 million before listing on Nasdaq First North

Adverty AB (publ) has during its IPO acquired a distribution of ownership to the required number of shareholders to qualify for a public listing of its share and has received a funding of SEK 36 million for its future expansion.Adverty AB (publ) (“Adverty”) has during its recent IPO acquired the required number of shareholders, in addition to its existing number of shareholders, to qualify for a public listing of the company’s share at Nasdaq First North. During the IPO period, Adverty has received funding of SEK 36 million, whereas SEK 8 million is subscribed for in the IPO, another SEK 8

Akelius lowers the risk

Akelius adjusts the finance policy.The new policy highlights the ambition to have a credit rating of BBB+ or better.The credit rating shall be minimum BBB. Starting from 2020: ‒     the loan to value should be lower than 40 percent ‒     the interest coverage ratio, excluding realized value growth, should exceed 2.0. Stockholm, 2018-10-19 Pål Ahlsén  CEO  +46 768 07 97 02  pal.ahlsen@akelius.se  This information is information that Akelius Residential Property AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was

Exercise of employee share options in Atea ASA ("the Company")

1. Employees in the Atea Group have exercised 898,905 options.Following the share option exercise the Board of Directors, pursuant to authorisation granted by the Company's Annual General Meeting, has decided to increase the Company's share capital by NOK 898,905 by issuing 898,905 new shares, of par value NOK 1. Following the increase, the Company's share capital is NOK 108,690,517 divided into 108,690,517 shares. The weighted average option exercise price is NOK 47,06. 2. Options exercised by primary insiders 19 October 2018:Aleksandr Novik has exercised 10,000 options in the

There are no items matching the current filter
There are no more items matching the current filter
Back to top